Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.48 USD

28.48
11,702,395

-0.04 (-0.14%)

Updated Oct 31, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal

by Zacks Equity Research

AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.

OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

by Zacks Equity Research

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.

The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis

Sheraz Mian headshot

Top Research Reports for Home Depot, salesforce & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE).

AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space

by Zacks Equity Research

AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.

Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

by Zacks Equity Research

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only

by Zacks Equity Research

The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.

Sweta Killa headshot

7 Best ETFs of the First Nine Months of 2021

by Sweta Killa

We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot

by Kinjel Shah

FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.

Mark Vickery headshot

Nike, Costco Report Better Earnings than Expected

by Mark Vickery

Both Nike and Costco beat bottom-line estimates in their subsequent quarters, but struggled to match on the top-line.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.

Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.

Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People

by Zacks Equity Research

FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.

J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection

by Zacks Equity Research

J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.

Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255

by Zacks Equity Research

Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study

by Zacks Equity Research

Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.

Company News for Sep 21, 2021

by Zacks Equity Research

Companies In The News Are: TSLA, AAL, PFE, BNTX, F.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $44.20, marking a +0.71% move from the previous day.

September Syndrome Deepens in Markets

by Zacks Equity Research

September Syndrome Deepens in Markets.

Mark Vickery headshot

Contagion Fears Squeeze Pre-Market Futures

by Mark Vickery

It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.

Kinjel Shah headshot

FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down

by Kinjel Shah

Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.

Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12

by Zacks Equity Research

Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.

AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet

by Zacks Equity Research

Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.

The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, HP, Kohl's, Macy's, LKQ and United States Steel